Participant flow

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib · Source last updated 2021-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cabozantinib (XL184) 60 mg tablet once daily Cabozantinib tablets

   id

   FG000

   title

   Cabozantinib (XL184)

2. description

   Oral cabozantinib-matched placebo tablet once daily Placebo tablets

   id

   FG001

   title

   Placebo

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         98

      2. group Id

         FG001

         num Subjects

         11

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         72

      2. group Id

         FG001

         num Subjects

         38

      type

      Clinical Deterioration

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      Lack of Efficacy

   4. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Lost to Follow-up

   5. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         3

      type

      Physician Decision

   6. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         6

      type

      Withdrawal by Subject

   7. reasons

      1. group Id

         FG000

         num Subjects

         206

      2. group Id

         FG001

         num Subjects

         152

      type

      Progressive Disease

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Protocol Violation

   9. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      No Study Treatment Given

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         470

      2. group Id

         FG001

         num Subjects

         237

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         73

      2. group Id

         FG001

         num Subjects

         26

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         397

      2. group Id

         FG001

         num Subjects

         211

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

First patient enrolled: 26 September 2013, Data cut-off date: 01 June 2017

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice